Midjourney Medical Runs Its Scanner Through a Spa to Sidestep the FDA — BFLY +17%, Data Is the Real Product
Midjourney Medical, the AI image company’s pivot into health hardware, carries more regulatory architecture than the original announcement conveyed.
The product is a 60-second full-body ultrasound scan. The distribution mechanism is what demands closer reading: Midjourney is routing the scanners through “Midjourney Spas” — a structural choice designed to keep the devices outside FDA medical device classification. The spa framing is not aesthetic. It is a regulatory strategy.
The Butterfly Network Connection
The scanners run on Butterfly Network’s ultrasound-on-chip technology. Butterfly Network (NYSE: BFLY) makes handheld ultrasound devices that consolidate a full imaging stack onto a semiconductor chip, enabling hardware small and cheap enough to operate far outside a clinical setting. When Midjourney Medical launched, BFLY shares jumped 17%.
That hardware combination — BFLY’s chip inside a wellness venue — positions the product as consumer health rather than clinical diagnostic. Under that framing, FDA Class II or Class III medical device requirements do not apply. The scanner gets to market faster, cheaper, and without the clinical validation burden of a conventional imaging device.
”A Bet On Data, Not Doctors”
Forbes called it directly: Midjourney Medical is a data play. A 60-second scan generates a dense, structured body map. Deployed across a Midjourney Spa network, the platform produces a longitudinal biometric dataset no healthcare institution has assembled before: normalized, recurring body imaging on millions of people who opted in for a wellness experience.
Business Insider captured the positioning: “Midjourney wants to map your body in 60 seconds and then send you to a sauna.”
The training data angle is immediate. Midjourney built its reputation generating images. Body scan data — 3D, high-resolution, structured — is training material for a generative health AI that does not yet exist at scale. The scanning operation builds the dataset while the spa business covers operating costs.
Regulatory Arbitrage as Template
If Midjourney’s spa mechanism survives scrutiny, it becomes a playbook. A device distributed through a wellness context, collecting biometric data under consumer consent rather than clinical protocol, at a fraction of the approval cost of regulated medical hardware.
The risk: the FDA determines intended use, not venue. If Midjourney’s marketing materials describe diagnostic output — “here is what this scan found about your body” — the spa location provides less regulatory cover than the structure implies. The company has not disclosed how scan results will be communicated to customers.
HN discussion flagged early framing errors in coverage: the scanner is not solely a consumer wellness device, and Midjourney has not characterized it as medical diagnosis. That ambiguity is exactly where the regulatory question lives.
Key Numbers
- BFLY share move on announcement: +17%
- Scan duration: 60 seconds
- Underlying technology: Butterfly Network ultrasound-on-chip (NYSE: BFLY)
- Distribution vehicle: Midjourney Spas
- FDA strategy: consumer wellness classification, not medical device